The positive outcome from the Phase 2 clinical trial of stenoparib, evidenced by tumor shrinkage and long-term disease stability, has significantly boosted investor confidence in Allarity Therapeutics. The decision to discontinue the trial early to focus on a follow-on study with FDA regulatory intent indicates a strong potential for future success and regulatory approval, which in turn has positively impacted the stock price.